News from all angles
(MedPage Today) -- Prophylactic use of the novel oral bradykinin B2 receptor antagonist deucrictibant substantially reduced hereditary angioedema (HAE) attacks, a pivotal phase III trial showed. For …
Redirecting to MedPage Today in 3 seconds...
Share this story with your network